Gilead Sciences Inc
XMUN:GIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Gilead Sciences Inc
XMUN:GIS
|
US |
|
A
|
Ally Financial Inc
LSE:0HD0
|
US |
|
L
|
Lloyds Banking Group PLC
XMUN:LLD
|
UK |
|
K
|
Kao Corp
SWB:KAO
|
JP |
|
G
|
Goldman Sachs BDC Inc
F:GSB
|
US |
|
L
|
L3harris Technologies Inc
DUS:HRS
|
US |
|
C
|
Carlisle Companies Inc
XBER:CLE
|
US |
|
Getty Realty Corp
NYSE:GTY
|
US |
|
Hanjaya Mandala Sampoerna Tbk PT
F:HSZ
|
ID |
|
T
|
Telefonica SA
DUS:TNE5
|
ES |
|
M
|
MacroGenics Inc
SWB:M55
|
US |
|
AZZ Inc
NYSE:AZZ
|
US |
|
Technip Energies NV
PAR:TE
|
FR |
|
Note AB (publ)
F:NQA
|
SE |
|
Datatec Ltd
OTC:DTTLF
|
ZA |
|
S
|
SosTravel.com SpA
OTC:SOSAF
|
IT |
|
O
|
Occidental Petroleum Corp
LSE:0KAK
|
US |
Gilead Sciences Inc
Gilead Sciences is a biopharmaceutical company that develops and sells prescription medicines, especially in antiviral treatments. Its best-known products have been used to treat HIV, hepatitis B and C, and it also sells medicines for cancer and inflammatory diseases. The company focuses on discovering drugs, testing them in clinical trials, getting them approved, and then manufacturing and marketing them to patients who need long-term treatment. Gilead makes money mainly by selling branded medicines through pharmacies, hospitals, and specialty distributors. Its customers are not individual consumers in the usual sense, but doctors, health systems, insurers, and government payers that decide which drugs are used and reimbursed. Because many of its medicines are prescription-only and protected by patents or other exclusivity, Gilead’s business depends on scientific research, regulatory approval, and strong relationships with the medical community. What makes Gilead different is its concentration in disease areas where patients often need ongoing therapy rather than one-time treatment. That gives the company a role similar to a specialist supplier inside the drug industry: it is known for deep expertise in antivirals and for building large, durable franchises around a few important medicine categories. It also grows by licensing, partnerships, and acquiring compounds or companies that fit those core areas.
Gilead Sciences is a biopharmaceutical company that develops and sells prescription medicines, especially in antiviral treatments. Its best-known products have been used to treat HIV, hepatitis B and C, and it also sells medicines for cancer and inflammatory diseases. The company focuses on discovering drugs, testing them in clinical trials, getting them approved, and then manufacturing and marketing them to patients who need long-term treatment.
Gilead makes money mainly by selling branded medicines through pharmacies, hospitals, and specialty distributors. Its customers are not individual consumers in the usual sense, but doctors, health systems, insurers, and government payers that decide which drugs are used and reimbursed. Because many of its medicines are prescription-only and protected by patents or other exclusivity, Gilead’s business depends on scientific research, regulatory approval, and strong relationships with the medical community.
What makes Gilead different is its concentration in disease areas where patients often need ongoing therapy rather than one-time treatment. That gives the company a role similar to a specialist supplier inside the drug industry: it is known for deep expertise in antivirals and for building large, durable franchises around a few important medicine categories. It also grows by licensing, partnerships, and acquiring compounds or companies that fit those core areas.
Beat and raise: Gilead said first-quarter performance was strong enough to lift full-year revenue guidance by $400 million, driven mainly by HIV, Trodelvy and Livdelzi.
Yeztugo surge: Yeztugo sales were $166 million in the quarter, up 72% sequentially and above expectations, prompting management to raise 2026 guidance for the product to $1 billion.
HIV strength: HIV sales grew 10% year over year, and management now expects the HIV business to grow about 8% in 2026, versus 6% previously.
Pipeline momentum: The company highlighted a wave of near-term catalysts, including an FDA decision on BIC/LEN in August, a December decision on Anito-cel, and multiple Phase III readouts later this year.
Margin discipline: First-quarter operating margin was 47%, and management said it remains committed to holding margins up even as it absorbs large acquisition-related costs.
Deal strategy: Gilead closed Arcellx and said Tubulis and Ouro are expected to close later this quarter, but it signaled that bigger M&A is less likely for the rest of 2026.
Management
Daniel P. O'Day is a prominent business executive known for his leadership in the pharmaceutical industry. He currently serves as the Chairman and Chief Executive Officer (CEO) of Gilead Sciences, Inc., a biopharmaceutical company that focuses on innovative therapeutics in areas of unmet medical need. O'Day joined Gilead in March 2019, bringing with him over three decades of experience in the healthcare sector. Before joining Gilead, O'Day spent a significant portion of his career at Roche, a leading global healthcare company based in Switzerland. He held various key positions at Roche, culminating in his role as the CEO of Roche Pharmaceuticals from 2012 to 2018. During his tenure at Roche, O'Day played an instrumental role in guiding the company's pharmaceutical business and expanding its global influence. O'Day's educational background includes a Bachelor's degree in Biology from Georgetown University and an MBA from Columbia University. His expertise in both scientific and business disciplines has been pivotal in his leadership roles, where he has consistently driven growth and innovation. Under O'Day's leadership, Gilead Sciences has continued to advance its research and development efforts, particularly in the areas of antiviral, oncology, and inflammatory diseases. His strategic focus on transformative therapies and commitment to addressing significant medical needs have been central to the company's mission.
Before joining Gilead, O'Day spent a significant portion of his career at Roche, a leading global healthcare company based in Switzerland. He held various key positions at Roche, culminating in his role as the CEO of Roche Pharmaceuticals from 2012 to 2018. During his tenure at Roche, O'Day played an instrumental role in guiding the company's pharmaceutical business and expanding its global influence.
O'Day's educational background includes a Bachelor's degree in Biology from Georgetown University and an MBA from Columbia University. His expertise in both scientific and business disciplines has been pivotal in his leadership roles, where he has consistently driven growth and innovation.
Under O'Day's leadership, Gilead Sciences has continued to advance its research and development efforts, particularly in the areas of antiviral, oncology, and inflammatory diseases. His strategic focus on transformative therapies and commitment to addressing significant medical needs have been central to the company's mission.
Andrew D. Dickinson is the Chief Financial Officer (CFO) at Gilead Sciences, Inc. He plays a crucial role in overseeing the financial operations of the company. Before becoming the CFO, Dickinson held several significant positions at Gilead, including Executive Vice President for Corporate Development and Strategy. In these roles, he was responsible for corporate development, mergers and acquisitions, and strategic planning. Before joining Gilead, Dickinson was a Managing Director in the investment banking department of Lazard, where he specialized in advising healthcare companies. He also practiced as a mergers and acquisitions attorney at the law firm of Cravath, Swaine & Moore. Dickinson holds a bachelor's degree from Amherst College and a J.D. from Columbia University School of Law. His extensive expertise in finance, law, and strategic business development have been instrumental in advancing Gilead’s business objectives.
Before joining Gilead, Dickinson was a Managing Director in the investment banking department of Lazard, where he specialized in advising healthcare companies. He also practiced as a mergers and acquisitions attorney at the law firm of Cravath, Swaine & Moore. Dickinson holds a bachelor's degree from Amherst College and a J.D. from Columbia University School of Law. His extensive expertise in finance, law, and strategic business development have been instrumental in advancing Gilead’s business objectives.
Deborah H. Telman, J.D., is a prominent executive serving as an Executive Vice President at Gilead Sciences, Inc. She plays a crucial role in overseeing the company's legal and government affairs. With a strong background in law and extensive experience in the pharmaceutical and biotech industries, Telman contributes significantly to shaping Gilead's strategic direction and ensuring compliance with regulatory standards. Before joining Gilead Sciences, Telman held various senior positions in other major companies. Her prior roles have included leadership positions in legal departments, where she provided counsel on matters related to corporate governance, mergers and acquisitions, intellectual property, and regulatory compliance. Telman holds a Juris Doctor degree, which has equipped her with the legal expertise essential for navigating the complex landscape of biotechnology and pharmaceuticals. Her leadership skills and legal acumen are pivotal in advancing Gilead's mission to deliver life-saving therapies worldwide. Her career is distinguished by a commitment to excellence, innovation, and ethical standards in the life sciences sector.
Before joining Gilead Sciences, Telman held various senior positions in other major companies. Her prior roles have included leadership positions in legal departments, where she provided counsel on matters related to corporate governance, mergers and acquisitions, intellectual property, and regulatory compliance.
Telman holds a Juris Doctor degree, which has equipped her with the legal expertise essential for navigating the complex landscape of biotechnology and pharmaceuticals. Her leadership skills and legal acumen are pivotal in advancing Gilead's mission to deliver life-saving therapies worldwide. Her career is distinguished by a commitment to excellence, innovation, and ethical standards in the life sciences sector.
Johanna Mercier is the Chief Commercial Officer at Gilead Sciences, Inc., a biopharmaceutical company known for its work in antiviral drugs. Prior to joining Gilead in 2019, Mercier worked for nearly 25 years at Bristol-Myers Squibb, where she held several leadership roles across the company. Her positions included serving as President & Head of U.S. and Large Markets, within the Worldwide Commercial organization. At Gilead, Mercier is responsible for the worldwide commercialization of the company’s products and oversees the global commercial operations. She holds a Bachelor of Science in Biology from the University of Montreal and an MBA from Concordia University in Canada. Known for her strategic and operational excellence, she has been instrumental in driving Gilead’s commercial strategies and expanding the company’s global reach. Mercier is also recognized for her commitment to fostering an inclusive workplace and mentoring the next generation of leaders in the biotech industry.
At Gilead, Mercier is responsible for the worldwide commercialization of the company’s products and oversees the global commercial operations. She holds a Bachelor of Science in Biology from the University of Montreal and an MBA from Concordia University in Canada. Known for her strategic and operational excellence, she has been instrumental in driving Gilead’s commercial strategies and expanding the company’s global reach. Mercier is also recognized for her commitment to fostering an inclusive workplace and mentoring the next generation of leaders in the biotech industry.
Dr. Merdad V. Parsey is a prominent figure in the pharmaceutical industry, serving as the Chief Medical Officer at Gilead Sciences, Inc. His role at Gilead involves overseeing the company's global clinical development and medical affairs organizations, contributing to the advancement of Gilead's innovative therapies. Dr. Parsey holds both a Doctor of Medicine (M.D.) and a Doctor of Philosophy (Ph.D.) degree, showcasing his comprehensive background in both clinical medicine and scientific research. Prior to joining Gilead, he has held significant positions in the biotechnology and pharmaceutical sectors, including leadership roles focused on clinical development and regulatory affairs. His career has been marked by a deep commitment to translational research and the development of treatments that address unmet medical needs. Dr. Parsey's expertise covers a broad range of therapeutic areas, and he is well-respected for his contributions to advancing drug development processes and fostering collaborations across the industry. Dr. Parsey's work is instrumental in driving Gilead’s efforts to develop groundbreaking treatments, and his leadership is a crucial element in the company's mission to improve health outcomes worldwide.
Dr. Parsey holds both a Doctor of Medicine (M.D.) and a Doctor of Philosophy (Ph.D.) degree, showcasing his comprehensive background in both clinical medicine and scientific research. Prior to joining Gilead, he has held significant positions in the biotechnology and pharmaceutical sectors, including leadership roles focused on clinical development and regulatory affairs.
His career has been marked by a deep commitment to translational research and the development of treatments that address unmet medical needs. Dr. Parsey's expertise covers a broad range of therapeutic areas, and he is well-respected for his contributions to advancing drug development processes and fostering collaborations across the industry.
Dr. Parsey's work is instrumental in driving Gilead’s efforts to develop groundbreaking treatments, and his leadership is a crucial element in the company's mission to improve health outcomes worldwide.
Jacquie Ross, C.F.A., is a notable executive and finance professional who serves as the Executive Vice President and Chief Financial Officer (CFO) of Gilead Sciences Inc. She joined Gilead Sciences, a leading biopharmaceutical company, where she plays a critical role in overseeing the company's financial strategy, planning, and operations. As a member of the executive leadership team, Ross contributes to shaping the financial vision and supporting Gilead's long-term growth objectives. Her background as a Chartered Financial Analyst (CFA) enhances her expertise in investment management and financial analysis, vital for steering the company's fiscal health. With extensive experience in corporate finance and strategic planning in the healthcare sector, Ross is instrumental in guiding Gilead through the complexities of the global pharmaceutical landscape.
Ms. Jyoti K. Mehra is a prominent executive at Gilead Sciences Inc., serving as the Executive Vice President for Human Resources. She joined Gilead Sciences in 2017 and has played a vital role in leading the company's global human resources strategy. Her leadership style emphasizes diversity, inclusion, and organizational development, aligning HR initiatives with Gilead's mission and business objectives. Before joining Gilead Sciences, Ms. Mehra held significant HR leadership roles at various esteemed organizations. She was with Novartis, where she contributed to global HR strategies, and also worked at Bristol-Myers Squibb, taking part in various leadership and managerial roles in HR. Her extensive experience in the pharmaceuticals industry has equipped her with profound insights into fostering an empowering work culture and achieving strategic organizational goals. Ms. Mehra's educational background includes an MBA from Cornell University, further solidifying her expertise in business and human resources management. Under her guidance, Gilead Sciences has strengthened its focus on employee development, engagement, and a strong corporate culture.
Before joining Gilead Sciences, Ms. Mehra held significant HR leadership roles at various esteemed organizations. She was with Novartis, where she contributed to global HR strategies, and also worked at Bristol-Myers Squibb, taking part in various leadership and managerial roles in HR. Her extensive experience in the pharmaceuticals industry has equipped her with profound insights into fostering an empowering work culture and achieving strategic organizational goals.
Ms. Mehra's educational background includes an MBA from Cornell University, further solidifying her expertise in business and human resources management. Under her guidance, Gilead Sciences has strengthened its focus on employee development, engagement, and a strong corporate culture.
Dr. Linda Slanec Higgins is a prominent figure in the biopharmaceutical industry, known for her extensive contributions to drug discovery and development. She serves as a key executive at Gilead Sciences Inc., where she has played a significant role in advancing the company's research and development efforts. Dr. Higgins holds a Ph.D. in Molecular Biology and brings a wealth of experience in biotechnology and pharmaceutical research. Before her tenure at Gilead Sciences, Dr. Higgins held various leadership positions in other biotech firms, where she was instrumental in driving innovative research initiatives and fostering strategic collaborations. Her expertise spans across several therapeutic areas, and she has been involved in numerous successful drug development programs. Dr. Higgins is also recognized for her leadership skills and her commitment to mentoring young scientists and fostering a collaborative research environment within the organizations she has worked with. Her contributions have had a substantial impact on the development of new therapies that address unmet medical needs.
Before her tenure at Gilead Sciences, Dr. Higgins held various leadership positions in other biotech firms, where she was instrumental in driving innovative research initiatives and fostering strategic collaborations. Her expertise spans across several therapeutic areas, and she has been involved in numerous successful drug development programs. Dr. Higgins is also recognized for her leadership skills and her commitment to mentoring young scientists and fostering a collaborative research environment within the organizations she has worked with. Her contributions have had a substantial impact on the development of new therapies that address unmet medical needs.
Dr. Rudolf Ertl is an accomplished executive at Gilead Sciences Inc. in the roles of executive director and senior director. His extensive expertise in drug product and device development and commercialization, complemented by his experience in manufacturing and strategic sourcing, has enabled Gilead Sciences Inc. to successfully manufacture and launch novel therapeutics globally. Equipped with dual doctoral degrees in Pharmaceutical Sciences and Applied Arts and Sciences alongside an M.B.A., Dr. Ertl also draws on practical experience as a licensed pharmacist. His remarkable career reflects his unwavering commitment to helping patients and Gilead Sciences Inc. get the best therapeutic solutions to those who need them most.
Equipped with dual doctoral degrees in Pharmaceutical Sciences and Applied Arts and Sciences alongside an M.B.A., Dr. Ertl also draws on practical experience as a licensed pharmacist. His remarkable career reflects his unwavering commitment to helping patients and Gilead Sciences Inc. get the best therapeutic solutions to those who need them most.
